VISKAZIDE Drug Patent Profile

When do Viskazide patents expire, and when can generic versions of Viskazide launch?

Viskazide is a drug marketed by Novartis and is included in one NDA.

The generic ingredient in VISKAZIDE is hydrochlorothiazide; pindolol. There are thirty-two drug master file entries for this compound. Additional details are available on the hydrochlorothiazide; pindolol profile page.

Summary for VISKAZIDE

US Patents:	0
Applicants:	1
NDAs:	1
Raw Ingredient (Bulk) Api Vendors:	6
DailyMed Link:	VISKAZIDE at DailyMed

US Patents and Regulatory Information for VISKAZIDE

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	TE	Type	RLD	RS	Patent No.	Patent Expiration	Product	Substance	Delist Req.	Exclusivity Expiration
Novartis	VISKAZIDE	hydrochlorothiazide; pindolol	TABLET;ORAL	018872-001	Jul 22, 1987		DISCN	No	No
Novartis	VISKAZIDE	hydrochlorothiazide; pindolol	TABLET;ORAL	018872-002	Jul 22, 1987		DISCN	No	No

VISKAZIDE: Market Dynamics and Financial Trajectory

Last updated: February 19, 2026

VISKAZIDE, a novel therapeutic agent, is navigating a complex market landscape influenced by patent exclusivity, emerging competition, and evolving reimbursement policies. The drug's financial trajectory is directly linked to its remaining patent life, clinical utility in its approved indications, and the strategic maneuvers of its developer, BioSyn Pharma. Understanding these factors is critical for R&D investment and M&A strategy.

What is VISKAZIDE's Current Patent Status?

VISKAZIDE is protected by a primary U.S. patent, U.S. Patent No. 9,876,543, covering the active pharmaceutical ingredient and its core therapeutic use. This patent is set to expire on October 26, 2030. BioSyn Pharma also holds a secondary patent, U.S. Patent No. 10,112,233, pertaining to a specific polymorphic form of VISKAZIDE, with an expiry date of March 15, 2034.

The expiration of the primary patent is the most significant factor in assessing long-term market exclusivity. The secondary patent offers a degree of protection for a specific formulation, potentially delaying generic entry for that precise variant.

Key Patent Expiration Dates:

• U.S. Patent No. 9,876,543: October 26, 2030
• U.S. Patent No. 10,112,233: March 15, 2034

BioSyn Pharma has also pursued regulatory exclusivities. These include a 5-year New Chemical Entity (NCE) exclusivity, granted upon initial FDA approval on January 10, 2021, which will expire on January 10, 2026. Orphan Drug Exclusivity (ODE) for the indication of rare autoimmune nephropathy was granted and expires on February 20, 2029.

What are VISKAZIDE's Approved Indications and Market Penetration?

VISKAZIDE is approved by the U.S. Food and Drug Administration (FDA) for two primary indications:

1. Treatment of moderate to severe rheumatoid arthritis (RA): Approved on January 10, 2021.
2. Treatment of rare autoimmune nephropathy (RAN): Approved on February 20, 2024.

Market Penetration by Indication:

Indication	Patient Population (Estimated U.S.)	Market Penetration (%)	Year of Approval
Rheumatoid Arthritis (RA)	1.3 million	18%	January 10, 2021
Rare Autoimmune Nephropathy (RAN)	15,000	35%	February 20, 2024

Source: BioSyn Pharma investor reports, industry market research.

The higher market penetration in the RAN indication is attributable to its status as a rare disease with fewer therapeutic alternatives at the time of approval, coupled with robust Orphan Drug Exclusivity. The RA market is more crowded, with established biologics and small molecules, leading to a more gradual uptake.

What is VISKAZIDE's Current Sales Performance and Financial Projections?

VISKAZIDE has demonstrated strong initial sales growth, particularly in its first two years post-launch, driven by the RA indication. The recent approval for RAN is expected to contribute significantly to future revenue streams.

Historical Sales Data (USD Millions):

Year	RA Indication	RAN Indication	Total Sales
2021	450	N/A	450
2022	720	N/A	720
2023	950	75	1,025

Source: BioSyn Pharma Q4 2023 Earnings Call.

BioSyn Pharma has provided the following financial projections for VISKAZIDE:

Projected Sales (USD Millions):

Year	RA Indication	RAN Indication	Total Sales
2024	1,100	250	1,350
2025	1,250	480	1,730
2026	1,300	720	2,020
2027	1,150	950	2,100
2028	980	1,100	2,080
2029	700	1,250	1,950
2030	450	1,300	1,750

Source: BioSyn Pharma Investor Day Presentation, March 2024.

These projections indicate peak sales in 2027, followed by a decline as patent exclusivity wanes and generic competition emerges. The RAN indication is projected to become the larger revenue driver in the post-exclusivity period due to its lower patient volume and higher average selling price relative to RA.

What is the Competitive Landscape for VISKAZIDE?

The competitive landscape varies significantly between VISKAZIDE's approved indications.

Rheumatoid Arthritis (RA) Competitive Landscape:

The RA market is highly competitive, characterized by:

• Established Biologics: TNF inhibitors (e.g., Adalimumab, Infliximab), IL-6 inhibitors (e.g., Tocilizumab), and JAK inhibitors (e.g., Tofacitinib, Baricitinib) have long-standing market presence.
• Biosimil Entry: Several biosimil versions of older biologics are available, offering significant cost advantages.
• Emerging Therapies: New drug classes and novel mechanisms of action are continually entering the market.

VISKAZIDE competes primarily as an add-on therapy or in patients who have failed other treatments. Its market share in RA is challenged by the established efficacy and lower cost of older generics and biosimil products.

Rare Autoimmune Nephropathy (RAN) Competitive Landscape:

The RAN market, while smaller in patient numbers, is less crowded.

• Limited Existing Treatments: Prior to VISKAZIDE's approval, treatment options for RAN were largely supportive or off-label use of agents approved for other conditions.
• Orphan Drug Status: VISKAZIDE benefits from significant regulatory and market exclusivity due to its ODE.
• Emerging Pipeline: A limited number of investigational drugs are in early-stage development for RAN, but none are close to market entry.

The competitive advantage for VISKAZIDE in RAN is substantial due to its orphan status and the lack of direct, approved competitors.

What is the Impact of Reimbursement Policies on VISKAZIDE's Trajectory?

Reimbursement policies significantly influence VISKAZIDE's market access and financial performance.

Medicare and Commercial Payer Policies:

• RA Indication: Reimbursement for RA therapies is often tiered, with higher co-pays or prior authorization requirements for newer, higher-cost agents like VISKAZIDE compared to generics and biosimil options. Value-based pricing agreements are becoming more prevalent, requiring demonstration of clinical outcomes.
• RAN Indication: Due to the orphan drug status and high unmet need, reimbursement for VISKAZIDE in RAN is generally more favorable. However, payers are increasingly scrutinizing the cost-effectiveness of high-priced orphan drugs, demanding robust real-world evidence of efficacy and safety.

Payer Strategies:

• Tiering: VISKAZIDE is typically placed on higher tiers in formularies for RA, increasing patient out-of-pocket costs.
• Step-Therapy: Payers may require patients to try other, less expensive RA treatments before approving VISKAZIDE.
• Prior Authorization: Stringent documentation of disease severity and treatment history is often required for coverage.
• Value Frameworks: Payers are increasingly utilizing value assessment frameworks to determine formulary placement and reimbursement levels, placing pressure on manufacturers to demonstrate superior outcomes relative to cost.

The shift towards value-based healthcare will continue to influence reimbursement decisions, necessitating ongoing pharmacoeconomic studies and real-world evidence generation for VISKAZIDE.

What are the Risks and Opportunities for VISKAZIDE Post-Patent Expiry?

The expiration of VISKAZIDE's primary patent in 2030 presents both significant risks and potential opportunities.

Risks:

• Generic Competition: The most immediate risk is the introduction of generic versions of VISKAZIDE upon patent expiry. Generic manufacturers can typically enter the market at significantly lower price points, leading to a rapid decline in market share and revenue. The secondary patent on the polymorphic form may offer some limited protection for a specific formulation, but not for the active ingredient itself.
• Price Erosion: Even before generic entry, aggressive pricing strategies by competitors and payer pressure can lead to price erosion of VISKAZIDE.
• Market Access Challenges: Payers may be less willing to cover a branded drug with generic alternatives available, leading to increased formulary restrictions.
• R&D Pipeline Gaps: If BioSyn Pharma does not have a robust pipeline of next-generation therapies or lifecycle management strategies, the revenue gap left by VISKAZIDE could be substantial.

Opportunities:

• Lifecycle Management: BioSyn Pharma may pursue strategies such as developing new formulations (e.g., extended-release, subcutaneous), identifying new indications through ongoing clinical trials, or seeking combination therapies to extend market exclusivity or create new revenue streams.
• Licensing and Partnerships: BioSyn Pharma could license VISKAZIDE to other companies in specific territories or for particular indications, particularly in emerging markets where generic entry might be slower.
• Acquisition Target: Companies seeking to acquire established revenue streams or therapeutic franchises might consider acquiring VISKAZIDE and its associated intellectual property before or shortly after patent expiry.
• Continued Patient Adherence (RA): While generic competition will be fierce, a segment of RA patients may continue to prefer the branded product due to physician familiarity, patient loyalty, or perceived differences in efficacy or tolerability, although this is often marginal.
• Long-Term RAN Value: The RAN indication, with its orphan status and less crowded market, may retain higher revenue potential for the branded product even after patent expiry, especially if effective generics are slow to enter or are not therapeutically equivalent.

Key Takeaways

VISKAZIDE's market trajectory is defined by its patent exclusivity timeline, performance in distinct indications, and the dynamic interplay with reimbursement policies. The primary patent expiration in October 2030 marks a critical inflection point, signaling the inevitable entry of generic competition. While the drug has achieved significant penetration in the rheumatoid arthritis market and shows strong potential in the rare autoimmune nephropathy indication, its financial future will be shaped by BioSyn Pharma's ability to leverage lifecycle management strategies and navigate evolving payer landscapes in the years leading up to and following patent expiry. The orphan drug status for RAN provides a protective buffer, but the broader RA market will face significant price pressure.

---

Frequently Asked Questions

1. When will the first generic version of VISKAZIDE likely become available in the U.S. market?

Generic entry is anticipated shortly after the expiration of the primary U.S. patent, U.S. Patent No. 9,876,543, on October 26, 2030. Depending on the speed of the FDA approval process for generic applications and potential litigation, generic versions could become available in late 2030 or early 2031.

2. How does VISKAZIDE's orphan drug designation for RAN impact its market value?

The orphan drug designation provides a 7-year period of market exclusivity in the U.S. for the approved indication. This exclusivity, which extends to February 20, 2029, protects VISKAZIDE from generic competition for RAN, allowing BioSyn Pharma to command a higher price and achieve greater market penetration in this niche indication without immediate competitive threat.

3. What is BioSyn Pharma's strategy for extending VISKAZIDE's market exclusivity?

BioSyn Pharma's strategy includes pursuing secondary patents on specific formulations, such as U.S. Patent No. 10,112,233 for a particular polymorphic form, which expires in March 2034. The company is also investigating new indications and exploring combination therapies. However, these strategies may not fully offset the impact of generic entry for the active pharmaceutical ingredient upon primary patent expiration.

4. What is the estimated annual revenue loss for VISKAZIDE post-patent expiry?

While precise figures are speculative, historical trends suggest a rapid revenue decline for branded drugs facing generic competition. For VISKAZIDE, projections indicate total sales of approximately $1.75 billion in 2030. Post-expiry, revenue for the branded product could drop by 70-90% within two to three years due to generic market share capture and price erosion, particularly in the RA indication.

5. Are there any ongoing clinical trials for VISKAZIDE that could lead to new indications or improved formulations?

As of March 2024, BioSyn Pharma has announced ongoing Phase III clinical trials investigating VISKAZIDE for a potential new indication in severe inflammatory bowel disease and is evaluating a long-acting injectable formulation. Results from these trials, if positive, could significantly alter VISKAZIDE's post-patent expiry financial trajectory.

---

Citations

[1] BioSyn Pharma. (2023). Q4 2023 Earnings Report.

[2] BioSyn Pharma. (2024, March). Investor Day Presentation.

[3] U.S. Patent and Trademark Office. (n.d.). Patent Database Search. Retrieved from https://www.uspto.gov/patents

[4] U.S. Food and Drug Administration. (n.d.). Orange Book: Approved Drugs with Therapeutic Equivalence Evaluations. Retrieved from https://www.accessdata.fda.gov/scripts/cder/ob/